Hangzhou TianMuShan Pharmaceutical EnterpriseLtd Past Earnings Performance
Past criteria checks 0/6
Hangzhou TianMuShan Pharmaceutical EnterpriseLtd's earnings have been declining at an average annual rate of -39.4%, while the Pharmaceuticals industry saw earnings growing at 9.2% annually. Revenues have been declining at an average rate of 24.5% per year.
Key information
-39.4%
Earnings growth rate
-39.5%
EPS growth rate
| Pharmaceuticals Industry Growth | 10.9% |
| Revenue growth rate | -24.5% |
| Return on equity | -86.0% |
| Net Margin | -28.2% |
| Next Earnings Update | 30 Aug 2024 |
Recent past performance updates
Revenue & Expenses Breakdown
How Hangzhou TianMuShan Pharmaceutical EnterpriseLtd makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Mar 24 | 138 | -39 | 51 | 0 |
| 31 Dec 23 | 122 | -38 | 44 | 0 |
| 30 Sep 23 | 117 | -65 | 39 | 2 |
| 30 Jun 23 | 108 | -70 | 48 | 2 |
| 31 Mar 23 | 105 | -71 | 56 | 2 |
| 31 Dec 22 | 109 | -68 | 57 | 2 |
| 30 Sep 22 | 126 | -45 | 66 | 0 |
| 30 Jun 22 | 122 | -45 | 69 | 1 |
| 31 Mar 22 | 134 | -33 | 66 | 1 |
| 31 Dec 21 | 147 | -30 | 67 | 1 |
| 30 Sep 21 | 146 | -52 | 67 | 0 |
| 30 Jun 21 | 173 | -44 | 73 | 0 |
| 31 Mar 21 | 190 | -44 | 80 | 1 |
| 31 Dec 20 | 207 | -41 | 89 | 1 |
| 30 Sep 20 | 238 | 49 | 104 | 4 |
| 30 Jun 20 | 260 | 46 | 121 | 4 |
| 31 Mar 20 | 277 | 52 | 143 | 6 |
| 31 Dec 19 | 297 | 51 | 153 | 5 |
| 30 Sep 19 | 287 | -20 | 143 | 10 |
| 30 Jun 19 | 284 | -18 | 130 | 9 |
| 31 Mar 19 | 344 | -9 | 115 | 6 |
| 31 Dec 18 | 358 | -10 | 113 | 8 |
| 30 Sep 18 | 382 | 7 | 120 | 0 |
| 30 Jun 18 | 353 | 25 | 108 | 0 |
| 31 Mar 18 | 243 | 9 | 87 | 0 |
| 31 Dec 17 | 176 | 8 | 70 | 0 |
| 30 Sep 17 | 131 | 10 | 48 | 0 |
| 30 Jun 17 | 118 | 2 | 47 | 0 |
| 31 Mar 17 | 122 | 3 | 44 | 0 |
| 31 Dec 16 | 124 | 1 | 46 | 0 |
| 30 Sep 16 | 104 | -9 | 50 | 0 |
| 30 Jun 16 | 102 | -24 | 48 | 0 |
| 31 Mar 16 | 95 | -23 | 46 | 0 |
| 31 Dec 15 | 95 | -22 | 42 | 0 |
| 30 Sep 15 | 104 | -12 | 39 | 0 |
| 30 Jun 15 | 107 | -2 | 38 | 0 |
| 31 Mar 15 | 132 | -2 | 42 | 0 |
| 31 Dec 14 | 149 | 3 | 49 | 0 |
| 30 Sep 14 | 190 | 7 | 58 | 0 |
| 30 Jun 14 | 227 | 1 | 66 | 0 |
| 31 Mar 14 | 248 | 0 | 70 | 0 |
| 31 Dec 13 | 281 | 2 | 72 | 0 |
| 30 Sep 13 | 267 | -62 | 112 | 0 |
Quality Earnings: 600671 is currently unprofitable.
Growing Profit Margin: 600671 is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: 600671 is unprofitable, and losses have increased over the past 5 years at a rate of 39.4% per year.
Accelerating Growth: Unable to compare 600671's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: 600671 is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (-0.8%).
Return on Equity
High ROE: 600671 has a negative Return on Equity (-85.98%), as it is currently unprofitable.